Fecal transplant for ulcerative colitis, metabolic syndrome, or recurrent C. diff
Treatments studied
Part of Digestive system, Hormones & metabolism clinical trials.
This study uses fecal microbiota transplantation (FMT) — transferring gut bacteria from a healthy donor — to see how it affects the gut microbiome in people with ulcerative colitis, metabolic syndrome, or recurrent C. difficile infection. It may help stabilize the gut bacteria and improve symptoms.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- If you have ulcerative colitis, it must be mild-to-moderate and you must have been on a stable treatment (like mesalamine or immunosuppressants) for at least 8 weeks.
- If you have metabolic syndrome, you must have at least three of these: high blood sugar, high blood pressure, high triglycerides, low HDL ('good') cholesterol, or a large waistline, and be on stable treatment for at least 8 weeks.
- If you have recurrent C. difficile infection, it must be mild and you must have had it more than once.
- You cannot have taken antibiotics within 4 weeks before the start (unless you are in the C. diff group).
- You cannot have had previous bowel surgery or a stoma, and must not have certain other active gut conditions (like celiac disease, IBS, or chronic pancreatitis) unless you have ulcerative colitis.
- You must be able to give informed consent, and for women, must not be pregnant or breastfeeding and must use effective birth control.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests fecal microbiota transplantation (a procedure that puts healthy donor bacteria into your gut) for left-sided ulcerative colitis. It compares results using donors from two different backgrounds to see if one works better.
This study looks at how well fecal microbiota transplantation (FMT) works over time and checks its safety. If you have received at least one FMT for a qualifying condition, you may be able to participate.
This trial tests whether one or multiple fecal transplants from a healthy donor can help treat both a recurring C. diff infection and active ulcerative colitis. It aims to find the best schedule for the procedure.
This study tests a stool-based treatment (fecal microbiota treatment) to help remove “carbapenem-resistant” bacteria living in the gut. If you carry these bacteria without being sick, the goal is to reduce or stop that colonization.
This Phase 1 study tests whether transferring healthy gut bacteria (a fecal microbiome transplant) can help children with repeated or moderate-to-severe C. difficile infection. It focuses on changing gut bacteria to reduce ongoing infection and symptoms.
This trial studies using a fecal microbiota transplant (FMT)—healthy gut bacteria moved from a screened donor—to help treat recurring or hard-to-control C. difficile infection. It may help restore a healthier gut environment when standard treatments keep failing or the infection returns.
Hear when a new Metabolic Syndrome (MetS) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.